Cypralis
Biotech company developing small-molecule inhibitors of cyclophilins for acute and chronic degenerative diseases. Operates a virtual R&D model using CROs, academic collaborations and strategic partners; maintains a compound collection and IP estate across multiple cyclophilin-inhibitor chemical classes and advances candidates through preclinical studies and clinical trials.
Industries
Nr. of Employees
medium (51-250)
Cypralis
Cambridge, Cambridgeshire, United Kingdom, Europe
Patents
Products
CC-4066
Intravenous small-molecule cyclophilin inhibitor candidate evaluated for prevention and treatment of acute kidney injury, organ preservation during transplantation and acute pancreatitis; completed Phase I clinical trials and planned for Phase II in transplantation-related delayed graft function.
CC-4066
Intravenous small-molecule cyclophilin inhibitor candidate evaluated for prevention and treatment of acute kidney injury, organ preservation during transplantation and acute pancreatitis; completed Phase I clinical trials and planned for Phase II in transplantation-related delayed graft function.
Services
Partnership-based discovery, joint research programmes and licensing agreements to develop cyclophilin inhibitor candidates with external pharmaceutical or academic partners.
Partnership-based discovery, joint research programmes and licensing agreements to develop cyclophilin inhibitor candidates with external pharmaceutical or academic partners.
Expertise Areas
- Small-molecule medicinal chemistry
- Structure-based drug design and macrocycles
- Preclinical in vivo pharmacology (AKI, pancreatitis, organ protection)
- Pharmacokinetics and formulation development (IV/oral/topical)
Key Technologies
- Small-molecule cyclophilin inhibition
- Macrocyclic synthetic chemistry
- Structure-based drug design
- In vivo animal models of organ injury
News & Updates
Publication reporting discovery of orally bioavailable macrocyclic cyclophilin inhibitors (featured article in The Journal of Medicinal Chemistry).
Joint research programme to generate CNS-penetrant, subtype-selective cyclophilin D inhibitors for neurodegenerative disease targets.
Awarded feasibility and early-stage funding by Innovate UK to generate subtype-selective cyclophilin D inhibitors targeting degenerative and fibrotic diseases.
Funding awarded to support generation of brain-penetrant, subtype-selective cyclophilin D inhibitors for neurodegenerative disease research and hit-to-lead activities.
Agreement to acquire a large library of cyclophilin inhibitor compounds and associated patents and know-how from an external company, expanding the structural diversity of the company's collection.
Publication reporting discovery of orally bioavailable macrocyclic cyclophilin inhibitors (featured article in The Journal of Medicinal Chemistry).
Joint research programme to generate CNS-penetrant, subtype-selective cyclophilin D inhibitors for neurodegenerative disease targets.
Awarded feasibility and early-stage funding by Innovate UK to generate subtype-selective cyclophilin D inhibitors targeting degenerative and fibrotic diseases.
Funding awarded to support generation of brain-penetrant, subtype-selective cyclophilin D inhibitors for neurodegenerative disease research and hit-to-lead activities.
Agreement to acquire a large library of cyclophilin inhibitor compounds and associated patents and know-how from an external company, expanding the structural diversity of the company's collection.